133 related articles for article (PubMed ID: 38914959)
1. Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study.
Zhu J; Ding X; Zhang J; Chen B; You X; Chen X; Chen T
BMC Cancer; 2024 Jun; 24(1):756. PubMed ID: 38914959
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
[TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
[TBL] [Abstract][Full Text] [Related]
5. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
Seethapathy H; Street S; Strohbehn I; Lee M; Zhao SH; Rusibamayila N; Chute DF; Gao X; Michaelson MD; Rahma OE; Choueiri TK; McGregor B; Sonpavde G; Salabao C; Kaymakcalan MD; Wei X; Gupta S; Motwani S; Leaf DE; Reynolds KL; Sise ME
Eur J Cancer; 2021 Nov; 157():50-58. PubMed ID: 34482189
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
8. Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.
Zhou P; Liu B; Shen N; Fan X; Lu S; Kong Z; Gao Y; Lv Z; Wang R
Ren Fail; 2024 Dec; 46(1):2326186. PubMed ID: 38466161
[TBL] [Abstract][Full Text] [Related]
9. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
10. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy.
Jin S; Shen Z; Li J; Liu X; Zhu Q; Li F; Shi Y; Lin P; Xu X; Chen X; Geng X; Ding X; Liu H
J Clin Pathol; 2024 Jun; 77(7):471-477. PubMed ID: 38242556
[TBL] [Abstract][Full Text] [Related]
12. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
Seethapathy H; Zhao S; Chute DF; Zubiri L; Oppong Y; Strohbehn I; Cortazar FB; Leaf DE; Mooradian MJ; Villani AC; Sullivan RJ; Reynolds K; Sise ME
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1692-1700. PubMed ID: 31672794
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.
Koks MS; Ocak G; Suelmann BBM; Hulsbergen-Veelken CAR; Haitjema S; Vianen ME; Verhaar MC; Kaasjager KAH; Khairoun M
PLoS One; 2021; 16(6):e0252978. PubMed ID: 34101756
[TBL] [Abstract][Full Text] [Related]
14. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
Li C; Li Z; Sun Q; Xiang Y; Liu A
Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors and the risk of acute kidney injury in cancer patients receiving immune checkpoint inhibitors: A Danish population-based cohort study.
Munch PV; Nørgaard M; Heide-Jørgensen U; Jensen SK; Birn H; Christiansen CF
Int J Cancer; 2024 Apr; 154(7):1164-1173. PubMed ID: 37983738
[TBL] [Abstract][Full Text] [Related]
16. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
17. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study.
Lumlertgul N; Vassallo P; Tydeman F; Lewis N; Hobill A; Weerapolchai K; Nordin NZ; Seylanova N; Martin L; Cennamo A; Wang Y; Rigg A; Shaunak N; Ostermann M
Eur J Cancer; 2023 Sep; 191():112967. PubMed ID: 37499561
[TBL] [Abstract][Full Text] [Related]
18. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
[No Abstract] [Full Text] [Related]
19. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study.
Shimamura Y; Watanabe S; Maeda T; Abe K; Ogawa Y; Takizawa H
Clin Exp Nephrol; 2021 May; 25(5):479-487. PubMed ID: 33471239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
